Executive Director, Head of Rare Cancer @AstraZeneca @Alexion Former Professor @Harvardmed Firm to find CURE for #RareCancer #GBM #DIPG #Sarcoma
Boston, MA
Joined September 2018
- Tweets838
- Following269
- Followers796
- Likes1.6K
Bakhos A. Tannous, PhD retweeted
Online Now: Activated T cell extracellular vesicle DNA transfer enhances antigen presentation and anti-tumor immunity dlvr.it/TSKVFp
Bakhos A. Tannous, PhD retweeted
Online Now: A photoreceptor state links aggressive brain tumors in children dlvr.it/TRbCvd
Bakhos A. Tannous, PhD retweeted
CAR T cells are laboratory-engineered immune cells that provide effective treatment for some cancers. Progress is being made towards creating these cells in vivo
go.nature.com/3NtYGY4
Bakhos A. Tannous, PhD retweeted
The role of ultra-processed food (UPF) in obesity | @NatureRevEndo —time to sound the alarm 🚨 on UPF! Nice review that focus on the biological link between UPF and Obesity nature.com/articles/s41574-0…
Bakhos A. Tannous, PhD retweeted
Pan-cancer human brain metastases atlas at single-cell resolution dlvr.it/TLw4ZN
Bakhos A. Tannous, PhD retweeted
In the latest issue! Serotonin transporter inhibits antitumor immunity through regulating the intratumoral serotonin axis dlvr.it/TLv0mQ
Bakhos A. Tannous, PhD retweeted
Recent research found that #temozolomide rechallenge is a common, safe, and effective second-line option for patients with MGMT-methylated, #IDHwildtype #GBM following first-line lomustine/temozolomide therapy.
Read the full article in our latest issue: bit.ly/4497BUq
Bakhos A. Tannous, PhD retweeted
Policy Corner by Abdullah H. Ishaque, MD, PhD (@ahishaque), @AbdiAidid, JD, LLM, and @gelarehzadeh, MD, PhD: Lessons from the Failure of Canada’s Artificial Intelligence and Data Act nejm.ai/4ekfI3Q
#AIinMedicine
ALT Page 1 of the Policy Corner article "Lessons from the Failure of Canada’s Artificial Intelligence and Data Act"
Bakhos A. Tannous, PhD retweeted
Super excited to share our newest piece out today @NatureRevCancer linking age-induced metabolic reprogramming to cancer development. nature.com/articles/s41568-0…
Bakhos A. Tannous, PhD retweeted
The more potent and bespoke immunotherapy vs cancer, the better. Today's example is a neoantigen vaccine vs melanoma
cell.com/cell/fulltext/S0092…
Bakhos A. Tannous, PhD retweeted
Online Now: KEAP1 and STK11/LKB1 alterations enhance vulnerability to ATR inhibition in KRAS mutant non-small cell lung cancer dlvr.it/TLrhCk
Bakhos A. Tannous, PhD retweeted
Online now: Niche-specific therapeutic targeting of myeloid cells in the central nervous system dlvr.it/TKYNlp
Bakhos A. Tannous, PhD retweeted
Good update of recommendation for LGG management in the era of vorssidenib. More trials in progress
@EANOassociation
@EORTC
@SapienzaRoma
@ESTRO_RT
@myESMO
Bakhos A. Tannous, PhD retweeted
“I see death’s random strikes, who it strikes, it slays and who it misses will to old age live out his days”—Zuhayr bin Abī Sulma (520-609 AD).
Bakhos A. Tannous, PhD retweeted
We proudly stand with the rare disease community, highlighting their resilience and inspiring our continued efforts to tackle the long diagnosis timeline and life-changing treatments. #RareDiseaseDay
Bakhos A. Tannous, PhD retweeted
For readers interested in bispecific antibodies as cancer therapies, here's a comprehensive review
nature.com/articles/s41573-0…
rdcu.be/d8sNz
Bakhos A. Tannous, PhD retweeted
#REVIEW 🚨
Hanahan, Michielin & Pittet discuss how, nearly all cell types in the tumour microenvironment can be programmed to mediate — as functionally distinct subtypes — immunosuppressive programmes.
📖 👇
bit.ly/4gg4rRn
Bakhos A. Tannous, PhD retweeted
NEW content online! Metabolic interplays between the tumour and the host shape the tumour macroenvironment bit.ly/3DW7Kj9
